| 40.47 -0.58 (-1.41%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 52.06 | 1-year : | 55.58 |
| Resists | First : | 44.57 | Second : | 47.59 |
| Pivot price | 43.04 |
|||
| Supports | First : | 39.7 | Second : | 33.03 |
| MAs | MA(5) : | 40.99 |
MA(20) : | 43.64 |
| MA(100) : | 37.05  |
MA(250) : | 28.68 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 13.5 |
D(3) : | 12.2 |
| RSI | RSI(14): 35.6 |
|||
| 52-week | High : | 52.03 | Low : | 18.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MRUS ] has closed above bottom band by 12.9%. Bollinger Bands are 2.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.5 - 41.73 | 41.73 - 41.91 |
| Low: | 39.28 - 39.6 | 39.6 - 39.86 |
| Close: | 39.99 - 40.47 | 40.47 - 40.87 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Wed, 17 Apr 2024
Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Movies UK
Tue, 16 Apr 2024
24,325 Shares in Merus (NASDAQ:MRUS) Acquired by HealthInvest Partners AB - MarketBeat
Mon, 08 Apr 2024
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the ... - GlobeNewswire
Thu, 28 Mar 2024
Merus stock rated Buy at Truist on strong drug candidate prospects - Investing.com
Wed, 06 Mar 2024
MRUS Stock Quote Price and Forecast - CNN
Wed, 06 Mar 2024
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 88 (%) |
| Shares Short | 3,440 (K) |
| Shares Short P.Month | 4,460 (K) |
| EPS | -3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.15 |
| Profit Margin | 0 % |
| Operating Margin | -531.9 % |
| Return on Assets (ttm) | -23.6 % |
| Return on Equity (ttm) | -51.4 % |
| Qtrly Rev. Growth | -16.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.74 |
| EBITDA (p.s.) | -2.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -142 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -13.5 |
| PEG Ratio | 0 |
| Price to Book value | 6.56 |
| Price to Sales | 54.04 |
| Price to Cash Flow | -16.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|